Citations

Clear

410 citation(s) found for "Shu, Yu".

Primary (1°) tumor location as an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance).
Lenz, Heinz‐Josef , Kabbarah, Omar , Qu, Xueping , Goldberg, Richard M. , Höchster, Howard S. , O’Neil, Bert H. , Blanke, Charles D. , Innocenti, Federico , Venook, Alan P. , Ou, Fang‐Shu , Niedzwiecki, Donna , Zemla, Tyler , Sanoff, Hanna K. , Mayer, Robert J. , Bertagnolli, Monica M.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 3503-3503

10.1200/jco.2017.35.15_suppl.3503 Get It

3503 Background: 80405 found no OS or Progression Free Survival (PFS) difference when bevacizumab (BV) or cetuximab (Cet) was added to 1st-line FOLFOX or FOLFIRI in All RAS wild type (wt) mCRC pts. There was a significant 1° side by biologic interaction (P int: OS = 0.008, PFS = 0.001) favoring pts with left-sided (L) 1°. Analyses of 1° tumors beyond All RAS includes Consensus Molecular Subtype (CMS), BRAF and MSI. (CMS results - see Lenz et al; BRAF -see Innocenti et al) We asked whether 1° tumor location - L vs right (R) - is an independent prognostic marker when these other molecular features are considered. Methods: We used a Cox proportional hazard model stratified by prior XRT and +/- adjuvant chemo; adjusted for age, gender, synchronous vs metachronous, CMS, MSI and BRAF status. Pts with transverse (T) tumors were excluded in this analysis. Results: Sidedness was determined in 782 pts (L - 472; R - 256; T -54). Molecular data from 728 pts (with L - and R-sided 1°s) was available as follows: KRAS -- 291, NRAS -393, BRAF - 393, MSI - 378, CMS - 533. L vs R mOS: 32.9 v 19.6 months (mo) (p < 0.0001). See Table for OS results in All RAS / BRAF wt and BRAF mutant (mut) pts. Sidedness (R vs L) is an independent prognostic marker even after adjusting for all these molecular features: HR = 1.392 (1.032, 1.878), p = 0.031. Conclusions: Primary tumor location is an independent prognostic factor when adjusted for age, gender, synchronous/metachronous, CMS, MSI and BRAF status. We are exploring clinical variables such as tumor burden, metastatic sites and measurability of disease in an attempt to explain the impact of sidedness. Support: U10CA188021, U10CA180882. Eli Lilly and Co, Genentech/Roche, Pfizer, Sanofi. Clinical trial information: NCT002655850. [Table: see text]
Exploring the association between renal cell carcinoma (RCC) and myeloid malignancies.
Shenoy, Niraj , Mudireddy, Mythri , Costello, Brian A. , Leibovich, Bradley C. , Thompson, R. Houston, Pagliaro, Lance C. , Ördög, Tamás , Patnaik, Mrinal M. , Tefferi, Ayalew , Begna, Kebede H. , Shenoy, Niraj , Leung, Nelson , Witzig, Thomas E. , Ou, Fang‐Shu

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: e13073-e13073

10.1200/jco.2017.35.15_suppl.e13073 Get It

e13073 Background: We observed several patients with a personal history of both RCC and myeloid malignancy, and aimed to explore a possible association, especially given the similarity in their epigenetic landscape, with both being characterized by widespread aberrant hypermethylation (Hu C et al, CCR 2014; Jiang Y et al, Blood 2009). Methods: Mayo Clinic’s ‘Advanced Cohort Explorer’ database was used to identify patients with a history of both RCC and a myeloid malignancy - Acute Myelogenous Leukemia (AML), Myeloproliferative Neoplasms (MPN), Myelodysplastic syndromes (MDS) - and to determine the clinical characteristics. The incidence of MDS in patients ≥65 years with a history of RCC was compared to that in the general population ≥65 years (SEER- Medicare database) as well as the general patient population at Mayo Clinic, using one sample test of proportions. Results: A total of 59 patients were identified, with both biopsy proven RCC and a myeloid malignancy during their life time (12 AML, 9 MPN, 9 low risk MDS and 29 intermediate- high risk MDS). The cohort was characterized by marked male predominance (4.4: 1). Median age at RCC diagnosis was 64 years (range 37-87) and myeloid malignancy was 75 years (range 44-90). 46/59 patients had the RCC antecedent, 10/59 concurrent and 3/59 subsequent to the myeloid malignancy with a median time of myeloid malignancy diagnosis after RCC diagnosis of 7.7 years. For patients ≥65 years, the risk of developing MDS with a history of stage I/II RCC and nephrectomy was 5.26 times that of the general population based on the SEER-Medicare database (Cogle, Blood 2011)(395/100,000 vs 75/100,000; p value < 0.001), and 3.07 times that of the general population at Mayo Clinic (395/100,000 vs 128.4/100,000; p value < 0. 001). Conclusions: We observed an association between RCC and myeloid malignancies, particularly MDS; with a history of RCC conferring a substantially increased risk of developing MDS. We hypothesize that the perturbation of epigenetic landscape in the form of widespread hypermethylation may explain, in part, the association between the two malignancies; and aim to explore the potential aberrancy of epigenetic regulators in our patient cohort with a genomic, epigenomic and transcriptomic analysis.
Genome-wide association study (GWAS) of response to androgen deprivation therapy (ADT) and survival in metastatic prostate cancer (PCa).
Pomerantz, Mark M., Wang, Victoria , Lee, Gwo‐Shu Mary , Hahn, Noah M. , Jarrard, David F. , Liu, Glenn , García, Jorge A. , DiPaola, Robert S. , Freedman, Matthew L. , Kantoff, Philip W. , Xie, Wanling , Kohli, Manish , Wang, Elaine, Chen, Yu‐Hui , Carducci, Michael A. , Sweeney, Christopher J.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 1540-1540

10.1200/jco.2016.34.15_suppl.1540 Get It

Transcriptional and post-transcriptional regulation of ribonucleotide reductase (RRM2) control its oncogenic role in prostate cancer progression.
Armenia, Joshua , Yoshikawa, Yuki , Gerke, Travis , Komura, Kazumasa , Lee, Gwo‐Shu Mary , Mucci, Lorelei A. , Mazzu, Ying Zhang , Chakraborty, Goutam , Atiq, Mohammad Omar , Stopsack, Konrad H. , Kantoff, Philip W.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 5044-5044

10.1200/jco.2018.36.15_suppl.5044 Get It

Effect of age, gender, and performance status (PS) on the duration results of adjuvant chemotherapy for stage III colon cancer: The IDEA collaboration.
Shields, Anthony F. , Sobrero, Alberto F. , Souglakos, Ioannis , Yamanaka, Takeharu , Vernerey, Déwi , Boukovinas, Ioannis , Kato, Takeshi , Kakolyris, Stylianos, Ou, Fang‐Shu , Paul, James , Yoshino, Takayuki , Taı̈eb, Julien , Shi, Qian , Kerr, Rachel , Labianca, Roberto , Torri, Valter , André, Thierry , Grothey, Axel , Meyerhardt, Jeffrey A. , Iveson, Timothy

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 3599-3599

10.1200/jco.2018.36.15_suppl.3599 Get It

Causal modeling of CALGB 80405 (Alliance) to identify network drivers of metastatic colorectal cancer (CRC).
Das, Rahul K, Innocenti, Federico , Cunha, Daniel Ferreira da , Rich, Kelly , Lenz, Heinz‐Josef , Niedzwiecki, Donna , Wuest, Diane, Hayete, Boris , Khalil, Iya, Niedzwiecki, Donna , Das, Rahul K, Furchtgott, Leon , Meyerhardt, Jeffrey A. , Nixon, Andrew B. , Cunha, Daniel, Rich, Kelly, O’Reilly, Eileen M. , Ou, Fang‐Shu , Latourelle, Jeanne C. , Venook, Alan P.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 3570-3570

10.1200/jco.2018.36.15_suppl.3570 Get It

A phase II study of pre- and post-operative gemcitabine and erlotinib plus pancreaticoduodenectomy (PD) for patients with resectable pancreatic ductal adenocarcinoma (PDAC): ACOSOG Z5041 trial (Alliance).
Wolff, Robert A. , Kindler, Hedy L. , Evans, Douglas B. , Misdraji, Joseph , Tamm, Eric P. , Sahani, Dushyant V., Moore, Malcolm J. , Newman, Elliot , Merchant, Nipun B. , Goff, Laura W. , Pisters, Peter W. T., Posner, Mitchell C. , (Alliance), ACOSOG, Wei, Alice C. , Ou, Fang‐Shu , Shi, Qian , O’Reilly, Eileen M. , Meyerhardt, Jeffrey A. , Deshpande, Vikram , Berlin, Jordan D. , (Alliance), ACOSOG

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 4112-4112

10.1200/jco.2018.36.15_suppl.4112 Get It

Survival outcomes from CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer.
Twohy, Erin , Meyers, Michael O. , Boffa, Daniel J., Mitchell, Kisha A. , Ilson, David H. , Goodman, Karyn A. , Hall, Nathan C. , Bekaii‐Saab, Tanios , Ou, Fang‐Shu , Perry, Kyle A. , Frankel, Wendy L. , Venook, Alan P. , O’Reilly, Eileen M.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 4012-4012

10.1200/jco.2018.36.15_suppl.4012 Get It

Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer
Walsh, Naomi , Hyland, Paula L. , Yang, Qi , Childs, Erica J., Collins, Irene , Wang, Zhaoming , Arslan, Alan A. , Bracci, Paige M. , Brennan, Paul , Canzian, Federico , Gallinger, Steven , Goodman, Gary E. , Goodman, Phyllis J. , Hung, Rayjean J, Kurtz, Robert C. , Scélo, Ghislaine , Shu, Xiao Ou , Visvanathan, Kala , consortia, PanScan and PanC4, Andreotti, Gabriella , Babić, Ana , Berndt, Sonja I. , Borgida, Ayelet , Bueno‐de‐Mesquita, Bas , Buring, Julie E. , Chaffee, Kari G. , Foretová, Lenka , Fuchs, Charles S. , Gaziano, J. Michael , Giovannucci, Edward, Hackert, Thilo , Haiman, Christopher A. , Hartge, Patricia, Hasan, Manal , Helzlsouer, Kathy J., Herman, Joseph M. , Holly, Elizabeth A., Hoover, Robert N. , Hung, Rayjean J, Janout, Vladimí­r , Klein, Eric A. , Laheru, Daniel A. , Lee, I‐Min , Oberg, Ann L. , Patel, Alpa V. , Peters, Ulrike , Porta, Miquel , Real, Francisco X. , Rothman, Nathaniel , Sesso, Howard D. , Strobel, Oliver , Thornquist, Mark, Wactawski‐Wende, Jean , Wareham, Nick, Weiderpass, Elisabete , Wentzensen, Nicolas , Wheeler, William, Zeleniuch‐Jacquotte, Anne , Kraft, Peter , Li, Donghui , Jacobs, Eric J. , Petersen, Gloria M. , Wolpin, Brian M. , Rabe, Kari G. , Hung, Rayjean J. , Cleary, Sean, Weiderpass, Elisabete , Arslan, Alan A , Canzian, Federico , Hung, Rayjean J , Wactawski-Wende, Jean , Wang, Zhaoming , Visvanathan, Kala , Klein, Eric A , Strobel, Oliver , Kraft, Peter , Porta, Miquel , Real, Francisco X , Zeleniuch-Jacquotte, Anne , Zhang, Han , Mocci, Evelina , Zhang, Mingfeng , Freeman, Laura E. Beane , Duell, Eric J. , Giles, Graham G. , Goggins, Michael , Hung, Rayjean J, Kooperberg, Charles , Malats, Núria , Marchand, Loı̈c Le , Neale, Rachel Ε. , Olson, Sara H. , Van Den Eeden, Stephen K , White, Emily , Zheng, Wei , consortia, PanScan and PanC4, Albanes, Demetrius , Bamlet, William R. , Boutron‐Ruault, Marie‐Christine , Brais, Lauren K , Chanock, Stephen Jacob , Cleary, Sean P. , Cotterchio, Michelle , Holcátová, Ivana , Hung, Rayjean J, Lu, Lingeng , Männistö, Satu , Milne, Roger L. , Orlow, Irene , Rothman, Nathaniel , Severi, Gianluca , Silverman, Debra T. , Sund, Malin , Tobias, Geoffrey S. , Wareham, Nick, Yu, Kai , Risch, Harvey A. , Ámundadóttir, Laufey T. , Yu, Kai , Klein, Alison P. , Stolzenberg‐Solomon, Rachael Z.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | August 15, 2018 | Volume: 111 | Issue: 6 | Pages: 557-567

10.1093/jnci/djy155 | PMID 30541042 Get It

Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance)
Blarigan, Erin L. Van , Ou, Fang‐Shu , Niedzwiecki, Donna , Zhang, Sui , Fuchs, Charles S. , Ogino, Shuji , Benson, A.B., Hantel, Alexander, Atkins, James N., Giovannucci, Edward L. , Meyerhardt, Jeffrey A. , Saltz, Leonard , Ogino, Shuji , Meyerhardt, Jeffrey A , Ou, Fang-Shu , Niedzwiecki, Donna , Saltz, Leonard B. , Mayer, Robert J. , Venook, Alan P. , Song, Mingyang

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | July 23, 2018 | Volume: 27 | Issue: 10 | Pages: 1227-1230

10.1158/1055-9965.epi-18-0487 | PMID 30038051 Get It

Abstract Background: Higher intake of long-chain ω-3 polyunsaturated fatty acids and nuts, rich plant sources of unsaturated fats, after colon cancer diagnosis are associated with improved survival. It is not known whether the amount or the distribution of other types of fat is associated with survival after colon cancer. Methods: We prospectively examined postdiagnostic total, animal, and vegetable fats, as well as the saturated, monounsaturated, polyunsaturated, and trans fat in relation to disease-free survival among 1,011 patients with stage III colon cancer. Patients were enrolled between 1999 and 2001 at the onset of adjuvant chemotherapy and followed for recurrence or death through 2009. Results: During median follow-up of 7 years, we observed 305 deaths and 81 recurrences (total events: 386). Neither total nor any specific type of dietary fat examined was statistically significantly associated with risk of cancer recurrence or death from any cause (disease-free survival) after stage III colon cancer. Conclusions: The amount and type (animal, vegetable, saturated, monounsaturated, polyunsaturated, and trans) of dietary fat consumed after colon cancer does not appear to be substantially associated with risk of recurrence or survival. Impact: Neither total nor major types (animal, vegetable, saturated, monounsaturated, polyunsaturated, and trans) of dietary fat consumed after colon cancer was associated with cancer recurrence or survival. Cancer Epidemiol Biomarkers Prev; 27(10); 1227–30. ©2018 AACR.